JP Patent

JP7301209B2 — ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の大規模調製のためのプロセスおよび中間体、ならびに２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミド酢酸塩の調製

Assigned to イーライ リリー アンド カンパニー · Expires 2023-06-30 · 3y expired

What this patent protects

Patent listed against lasmiditan-succinate.

Drugs covered by this patent

Patent Metadata

Patent number
JP7301209B2
Jurisdiction
JP
Classification
—
Expires
2023-06-30
Drug substance claim
No
Drug product claim
No
Assignee
イーライ リリー アンド カンパニー
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.